A new method for in vivo analysis of parathyroid hormone-calcium set point in mice

Yasuo Imanishi, Charles B. Hall, Marilyn Sablosky, Edward M. Brown, Andrew Arnold

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Although methods for measuring the parathyroid hormone (PTH)-calcium set point in vivo in humans and large animals exist, translating such methods to the increasingly important mouse model poses considerable challenges. We also found that manipulation of dietary calcium does not yield sufficiently high or low serum calcium levels to achieve the minimum and maximum PTH levels needed for set point estimations. Therefore, we developed a new method for in vivo evaluation of the relative set point in mice. Intraperitoneal injection of calcium gluconate caused progressive increases in serum calcium over 120 minutes, with corresponding decreases in serum PTH levels. Intraperitoneal injection of Na2-EGTA caused a nadir of serum calcium at 30 minutes and a corresponding peak value of serum PTH. The lowest and highest serum calcium concentrations achieved were 6.7 mg/dl and 10.0 mg/dl, respectively. Linear regression analyses indicated high correlation coefficients (serum calcium vs. serum PTH; r = 0.969). To obtain the additional data points needed for set point estimation, blood was collected 30 minutes after intraperitoneal injection by tail nicking from three mice once a day, on 8 consecutive days, using multiple doses of calcium gluconate or Na2-EGTA. The lowest and highest serum calcium concentrations achieved were 5.0 mg/dl and 11.4 mg/dl. Maximum and minimum PTH levels were indeed observed, and a sigmoidal curve with a set point of 7.8 mg/dl was readily generated by the four-parameter model that was fit using a nonlinear mixed effects statistical approach. This protocol for in vivo set point analysis should be applicable in the future study of multiple genetically engineered and pharmacologically treated mouse models.

Original languageEnglish (US)
Pages (from-to)1656-1661
Number of pages6
JournalJournal of Bone and Mineral Research
Volume17
Issue number9
StatePublished - Sep 2002

Fingerprint

Parathyroid Hormone
Calcium
Serum
Intraperitoneal Injections
Calcium Gluconate
Egtazic Acid
Dietary Calcium
Tail
Linear Models
Regression Analysis

Keywords

  • Genetically engineered mice
  • Hyperparathyroidism
  • Nonlinear mixed effects
  • Parathyroid hormone
  • Parathyroid tumor

ASJC Scopus subject areas

  • Surgery

Cite this

A new method for in vivo analysis of parathyroid hormone-calcium set point in mice. / Imanishi, Yasuo; Hall, Charles B.; Sablosky, Marilyn; Brown, Edward M.; Arnold, Andrew.

In: Journal of Bone and Mineral Research, Vol. 17, No. 9, 09.2002, p. 1656-1661.

Research output: Contribution to journalArticle

Imanishi, Y, Hall, CB, Sablosky, M, Brown, EM & Arnold, A 2002, 'A new method for in vivo analysis of parathyroid hormone-calcium set point in mice', Journal of Bone and Mineral Research, vol. 17, no. 9, pp. 1656-1661.
Imanishi, Yasuo ; Hall, Charles B. ; Sablosky, Marilyn ; Brown, Edward M. ; Arnold, Andrew. / A new method for in vivo analysis of parathyroid hormone-calcium set point in mice. In: Journal of Bone and Mineral Research. 2002 ; Vol. 17, No. 9. pp. 1656-1661.
@article{702e5f68b853467d9b6373677d3296d2,
title = "A new method for in vivo analysis of parathyroid hormone-calcium set point in mice",
abstract = "Although methods for measuring the parathyroid hormone (PTH)-calcium set point in vivo in humans and large animals exist, translating such methods to the increasingly important mouse model poses considerable challenges. We also found that manipulation of dietary calcium does not yield sufficiently high or low serum calcium levels to achieve the minimum and maximum PTH levels needed for set point estimations. Therefore, we developed a new method for in vivo evaluation of the relative set point in mice. Intraperitoneal injection of calcium gluconate caused progressive increases in serum calcium over 120 minutes, with corresponding decreases in serum PTH levels. Intraperitoneal injection of Na2-EGTA caused a nadir of serum calcium at 30 minutes and a corresponding peak value of serum PTH. The lowest and highest serum calcium concentrations achieved were 6.7 mg/dl and 10.0 mg/dl, respectively. Linear regression analyses indicated high correlation coefficients (serum calcium vs. serum PTH; r = 0.969). To obtain the additional data points needed for set point estimation, blood was collected 30 minutes after intraperitoneal injection by tail nicking from three mice once a day, on 8 consecutive days, using multiple doses of calcium gluconate or Na2-EGTA. The lowest and highest serum calcium concentrations achieved were 5.0 mg/dl and 11.4 mg/dl. Maximum and minimum PTH levels were indeed observed, and a sigmoidal curve with a set point of 7.8 mg/dl was readily generated by the four-parameter model that was fit using a nonlinear mixed effects statistical approach. This protocol for in vivo set point analysis should be applicable in the future study of multiple genetically engineered and pharmacologically treated mouse models.",
keywords = "Genetically engineered mice, Hyperparathyroidism, Nonlinear mixed effects, Parathyroid hormone, Parathyroid tumor",
author = "Yasuo Imanishi and Hall, {Charles B.} and Marilyn Sablosky and Brown, {Edward M.} and Andrew Arnold",
year = "2002",
month = "9",
language = "English (US)",
volume = "17",
pages = "1656--1661",
journal = "Journal of Bone and Mineral Research",
issn = "0884-0431",
publisher = "Wiley-Blackwell",
number = "9",

}

TY - JOUR

T1 - A new method for in vivo analysis of parathyroid hormone-calcium set point in mice

AU - Imanishi, Yasuo

AU - Hall, Charles B.

AU - Sablosky, Marilyn

AU - Brown, Edward M.

AU - Arnold, Andrew

PY - 2002/9

Y1 - 2002/9

N2 - Although methods for measuring the parathyroid hormone (PTH)-calcium set point in vivo in humans and large animals exist, translating such methods to the increasingly important mouse model poses considerable challenges. We also found that manipulation of dietary calcium does not yield sufficiently high or low serum calcium levels to achieve the minimum and maximum PTH levels needed for set point estimations. Therefore, we developed a new method for in vivo evaluation of the relative set point in mice. Intraperitoneal injection of calcium gluconate caused progressive increases in serum calcium over 120 minutes, with corresponding decreases in serum PTH levels. Intraperitoneal injection of Na2-EGTA caused a nadir of serum calcium at 30 minutes and a corresponding peak value of serum PTH. The lowest and highest serum calcium concentrations achieved were 6.7 mg/dl and 10.0 mg/dl, respectively. Linear regression analyses indicated high correlation coefficients (serum calcium vs. serum PTH; r = 0.969). To obtain the additional data points needed for set point estimation, blood was collected 30 minutes after intraperitoneal injection by tail nicking from three mice once a day, on 8 consecutive days, using multiple doses of calcium gluconate or Na2-EGTA. The lowest and highest serum calcium concentrations achieved were 5.0 mg/dl and 11.4 mg/dl. Maximum and minimum PTH levels were indeed observed, and a sigmoidal curve with a set point of 7.8 mg/dl was readily generated by the four-parameter model that was fit using a nonlinear mixed effects statistical approach. This protocol for in vivo set point analysis should be applicable in the future study of multiple genetically engineered and pharmacologically treated mouse models.

AB - Although methods for measuring the parathyroid hormone (PTH)-calcium set point in vivo in humans and large animals exist, translating such methods to the increasingly important mouse model poses considerable challenges. We also found that manipulation of dietary calcium does not yield sufficiently high or low serum calcium levels to achieve the minimum and maximum PTH levels needed for set point estimations. Therefore, we developed a new method for in vivo evaluation of the relative set point in mice. Intraperitoneal injection of calcium gluconate caused progressive increases in serum calcium over 120 minutes, with corresponding decreases in serum PTH levels. Intraperitoneal injection of Na2-EGTA caused a nadir of serum calcium at 30 minutes and a corresponding peak value of serum PTH. The lowest and highest serum calcium concentrations achieved were 6.7 mg/dl and 10.0 mg/dl, respectively. Linear regression analyses indicated high correlation coefficients (serum calcium vs. serum PTH; r = 0.969). To obtain the additional data points needed for set point estimation, blood was collected 30 minutes after intraperitoneal injection by tail nicking from three mice once a day, on 8 consecutive days, using multiple doses of calcium gluconate or Na2-EGTA. The lowest and highest serum calcium concentrations achieved were 5.0 mg/dl and 11.4 mg/dl. Maximum and minimum PTH levels were indeed observed, and a sigmoidal curve with a set point of 7.8 mg/dl was readily generated by the four-parameter model that was fit using a nonlinear mixed effects statistical approach. This protocol for in vivo set point analysis should be applicable in the future study of multiple genetically engineered and pharmacologically treated mouse models.

KW - Genetically engineered mice

KW - Hyperparathyroidism

KW - Nonlinear mixed effects

KW - Parathyroid hormone

KW - Parathyroid tumor

UR - http://www.scopus.com/inward/record.url?scp=0036708155&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036708155&partnerID=8YFLogxK

M3 - Article

VL - 17

SP - 1656

EP - 1661

JO - Journal of Bone and Mineral Research

JF - Journal of Bone and Mineral Research

SN - 0884-0431

IS - 9

ER -